Navigation Links
Amarin Announces Successful Completion of Offering of American Depositary Shares
Date:1/11/2011

ute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101, the active ingredient in which is ethyl-EPA (ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.Investor Contact Information:John F. TheroPresident In U.S.: +1 (860) 572-4979investor.relations@amarincorp.comLee M. SternThe Trout GroupIn U.S.: +1 (646) 378-2922lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D.Russo PartnersIn U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office)+1 (347) 591-8785 (mobile)david.schull@russopartnersllc.commartina.schwarzkopf@russopar
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... The global Bioinformatics ... sectors, products & services and application. And the rising ... increasing demand of advanced drugs for the diagnosis ... growth for bioinformatics market. The implementation of information ... as bioinformatics. Decreasing cost of DNA sequencing, continuous ...
(Date:9/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r8v22b/regulatory ) has announced the ... (London, UK - September 24-25, 2015)" conference to ... provides an introduction to Pharmaceutical Regulatory Affairs and the ... for those working in a support staff role. ... regulatory procedures required to register products in ...
(Date:9/1/2015)... , September 1, 2015 - ... GARFIELD-AF R egistry data presented at ... on the evolution of manag ... -   The first-ever two-year outcomes from ... ESC Congress 2015 expose that all-cause death was the most frequent major event ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... Dental Economics, the author explained how many dental practices across the country are ... Assisted Manufacturing) technology. According to Beverly Hills cosmetic dentist Dr. Sam Saleh of ...
(Date:9/1/2015)... ... , ... According to a study published August 25th in the ... a three year study about weight loss and diabetes were far more likely to ... surgery at the onset of the trial. In fact, the participants in the trial ...
(Date:9/1/2015)... ... 2015 , ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted ... on Thursday, Oct. 1, at the La Valencia Hotel. The presentation, on the eve ... fashion and professional hair, makeup and nail design. , The evening of beauty ...
(Date:9/1/2015)... ... ... Georgia State University and its partners have introduced a ... assaults on their campuses. , The free, evidence-based survey was developed by the ... student affairs professionals responding to calls by the Obama Administration to strengthen efforts ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... collaboration, announces Splashtop Business for Remote Support , a solution optimized for ... Unhappy with the escalating renewal prices and inadequate customer services of existing ...
Breaking Medicine News(10 mins):Health News:Article on CAD/CAM Dental Technology Highlights the Advantages of 21st Century Dentistry, Notes Ora Dentistry Spa 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... , , , ... Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever ... , PHILADELPHIA, Sept. 2 Pfizer Inc. ignored a ... clinically superior to the significantly less expensive, generic vancomycin when its ...
... , , , ... DIET ), a leading provider of online weight loss services, ... creative boutique that specializes in DRTV commercials, to lead creative turnaround beginning ... service. , , "We are really impressed by ...
... 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that it has signed an agreement with ... collaborate on marketing,efforts and possible vaccine supply efforts to ... The agreement follows meetings between ...
... of the body,s immune system in the development of diseases ... skin cancer), type 1 diabetes, autoimmune liver disease, and in ... paved the way for a pioneering research programme which aims ... find ways to extract specific cells which play a role ...
... , , , , ... STRM ) announced today that it will release second quarter ... on Wednesday, September 9, 2009 after the market closes. The Company will ... Wednesday, September 9 at 4:30 p.m. ET. , , ...
... Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... of BioMarin, will present a company update at the Thomas Weisel Partners ... ET. , , Interested parties may access ... of the BioMarin website, www.BMRN.com . A replay ...
Cached Medicine News:Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 2Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 3Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 4Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 5Health News:eDiets.com Selects Karlin+Pimsler to Lead Creative Turnaround 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 3Health News:Biomedical Research Centre developing enhanced cells as therapies 2Health News:Biomedical Research Centre developing enhanced cells as therapies 3Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 2Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 3Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: